Last reviewed · How we verify

Biosensors Europe SA — Portfolio Competitive Intelligence Brief

Biosensors Europe SA pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dual Anti Platelet Therapy Dual Anti Platelet Therapy phase 3 Antiplatelet agent combination Thromboxane A2 pathway and P2Y12 receptor Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Tiantan Hospital · 1 shared drug class
  2. Inova Health Care Services · 1 shared drug class
  3. Kyunghee University Medical Center · 1 shared drug class
  4. Seoul National University Hospital · 1 shared drug class
  5. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
  6. University Hospital, Bordeaux · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biosensors Europe SA:

Cite this brief

Drug Landscape (2026). Biosensors Europe SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biosensors-europe-sa. Accessed 2026-05-18.

Related